PMID- 21601310
OWN - NLM
STAT- MEDLINE
DCOM- 20120229
LR  - 20120116
IS  - 1097-6787 (Electronic)
IS  - 0190-9622 (Linking)
VI  - 66
IP  - 2
DP  - 2012 Feb
TI  - Pompholyx and eczematous reactions associated with intravenous immunoglobulin 
      therapy.
PG  - 312-6
LID - 10.1016/j.jaad.2010.12.034 [doi]
AB  - INTRODUCTION: Intravenous immunoglobulin (IVIG) is used to treat many 
      inflammatory and autoimmune disorders and although generally well tolerated, 
      cutaneous side effects occur. OBJECTIVE: We reviewed reports of pompholyx and 
      eczematous reactions associated with IVIG. METHODS: A literature search was 
      performed using the PubMed and MEDLINE databases with the search terms 
      "intravenous immunoglobulin pompholyx," "intravenous immunoglobulin eczema," 
      "intravenous immunoglobulin cutaneous adverse effects," "intravenous 
      immunoglobulin cutaneous effects," "intravenous immunoglobulin skin effects," and 
      "intravenous immunoglobulin adverse effects." Relevant English-language articles 
      or articles in other languages cited in English-language articles were included. 
      RESULTS: We identified 64 cases of eczematous reactions associated with IVIG 
      therapy, including a patient treated on our inpatient consult service. In 
      reported cases, the majority of patients (62.5%) had pompholyx alone or a 
      combination of pompholyx on the hands or feet and two or fewer additional body 
      surfaces involved. The majority of reported cases (75%) experienced the 
      eczematous reaction after their first IVIG treatment. Neurologic conditions were 
      the most common (85.9%) diseases for which IVIG was used. Most patients responded 
      well to topical steroids or did not require treatment. LIMITATIONS: Some reported 
      cases had insufficient descriptions to be included in this review. A literature 
      review may underestimate the frequency of eczematous reactions to IVIG because 
      these reactions are often limited and may not be reported. CONCLUSIONS: With the 
      use of IVIG increasing, it is important for dermatologists to recognize this 
      cutaneous side effect of IVIG.
CI  - Copyright (c) 2011 American Academy of Dermatology, Inc. Published by Mosby, Inc. 
      All rights reserved.
FAU - Gerstenblith, Meg R
AU  - Gerstenblith MR
AD  - Department of Dermatology, Johns Hopkins School of Medicine, Baltimore, Maryland, 
      USA. meg.gerstenblith@uhhospitals.org
FAU - Antony, Ashley K
AU  - Antony AK
FAU - Junkins-Hopkins, Jacqueline M
AU  - Junkins-Hopkins JM
FAU - Abuav, Rachel
AU  - Abuav R
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20110520
PL  - United States
TA  - J Am Acad Dermatol
JT  - Journal of the American Academy of Dermatology
JID - 7907132
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Steroids)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Autoimmune Diseases/drug therapy
MH  - Child
MH  - Eczema/*chemically induced/drug therapy
MH  - Eczema, Dyshidrotic/*chemically induced/drug therapy
MH  - Female
MH  - Humans
MH  - Immunization, Passive/adverse effects
MH  - Immunoglobulins, Intravenous/*adverse effects
MH  - Male
MH  - Middle Aged
MH  - Steroids/therapeutic use
EDAT- 2011/05/24 06:00
MHDA- 2012/03/01 06:00
CRDT- 2011/05/24 06:00
PHST- 2010/10/28 00:00 [received]
PHST- 2010/12/30 00:00 [revised]
PHST- 2010/12/30 00:00 [accepted]
PHST- 2011/05/24 06:00 [entrez]
PHST- 2011/05/24 06:00 [pubmed]
PHST- 2012/03/01 06:00 [medline]
AID - S0190-9622(11)00006-5 [pii]
AID - 10.1016/j.jaad.2010.12.034 [doi]
PST - ppublish
SO  - J Am Acad Dermatol. 2012 Feb;66(2):312-6. doi: 10.1016/j.jaad.2010.12.034. Epub 
      2011 May 20.